Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: Lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists

American Heart Journal

Volumn 143, Issue 4, 2002, Pages 594-601

  Mazur, Wojciech ^a   Kaluza, Grzegorz L ^a   Sapp, Shelly ^b   Balog, Craig ^b   Topol, Eric J ^b   Mark, Daniel B ^d   Ellis, Stephen G ^b   Kereiakes, Dean J ^c   Lincoff, A Michael ^b   Kleiman, Neal S ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Lindner Center for Cardiovascular Research

^d Duke Clinical Research Organization   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EVALUATION; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK FACTOR; STENOSIS; STENT; THROMBUS;

EID: 0036241698     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.121519     Document Type: Article

References (21)

1. Coronary artery stents
2. Acute and nine-month clinical outcomes after "suboptimal" coronary stenting: Results from the STent Anti-thrombotic Regimen Study (STARS) registry
3. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
4. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
7. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty
8. Intracoronary stenting and risk for major adverse cardiac events during the first month
9. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology
10. The benefit of abciximab in percutaneous coronary revascularization is not device-specific
11. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
12. Audit and quality control in angioplasty in Europe: Procedural results of the AQUA Study 1997: Assessment of 250 randomly selected coronary interventions performed in 25 centres of five European countries
13. A retrospective study of 6,671 patients comparing coronary stenting and balloon angioplasty
14. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial
15. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial
16. Direct coronary stenting without predilation
17. Immediate and late outcomes after direct stent implantation without balloon predilation
18. Evolution of improved antithrombotic and antiplatelet agents: Genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET)
19. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty
20. Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In-hospital and six-month outcomes
21. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?"